None listed
Conditions
Interventions
Drug : Treatment group: Take two weeks of erdosteine and NSAIDs
Control group: Take two weeks of NSAIDs
Sponsors
Inha University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria Diagnosis standard for acute sinusitis ? One or more of the symptoms of nasal obstruction/nasal discharge/posterior nasal drip ? One or more symptoms of sinus pain/Pressure or hyposmia/anosmia ? Observation of purulent discharge and mucous membrane edema ? Symptom duration less than 12 weeks
Exclusion criteria
Exclusion criteria: Exclusion criteria (1) Condra-indication for Erdosteine treatment ? Patient with severe liver failure/ liver cirrhosis, patient with enzyme deficiency related to metionine metabolism ? Patients with severe renal failure ? Patient with peptic ulcer ? Pregnancy/lactating women (2) A history of nose surgery within the last three months (3) Chronic sinusitis and nasal polyp identified by nasal endoscopy, X-ray, CT, etc. (4) Subjects who participated in other clinical trials within one month prior to participating in this clinical trial (5) Subjects deemed inappropriate for participation in this study by the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Symptom improvement(VAS score: nasal congestion, rhinorrhea, facial tenderness pain, hyposmia);improvement in nose symptom (SNOT-22 score) | — |
Secondary
| Measure | Time frame |
|---|---|
| improvement of endoscopic findings;improvement of simple paranasal X-ray findings | — |
Countries
Korea, Republic of
Contacts
Public ContactSujeong Kim
Inha University Hospital
Outcome results
None listed